Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results

Table 2 Donor-specific HLA antibody specificity and C1q-fixing assessment in PE-IVIG-RTX and control groups at diagnosis n (%)

	PE-IVIG-RTX group (n = 9)	Control group (n = 12)	P-value
Class I	2/9 (22.2)	6/12 (50)
Class II	5/9 (55.6)	2/12 (16.7)	0.166
Class I + II	2/9 (22.2)	4/12 (33.3)
MFI at diagnosis1	9800 (2700 – 24400)	4500 (900-24700)	0.327
C1q-fixing DSA1	4/9 (44.4)	4/102 (40)	0.845

¹Considering immunodominant antibody;

²Two patients were not tested for serum unavailability. DSA: Donor-specific antibodies.